Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas

BMC Clinical Pathology

Volumn 12, Issue , 2012, Pages

  Sorbye, Sveinung W ^a,b   Kilvaer, Thomas K ^b   Valkov, Andrej ^a,b   Donnem, Tom ^a,b   Smeland, Eivind ^c   Al Shibli, Khalid ^b,c   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; ANGIOSARCOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD20+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LIPOSARCOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROBLASTIC TUMOR; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MULTIMODALITY CANCER THERAPY; MYOFIBROBLASTIC TUMOR; NERVE SHEATH TUMOR; PRESCHOOL CHILD; RHABDOMYOSARCOMA; SCHOOL CHILD; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; T LYMPHOCYTE; TISSUE MICROARRAY; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

EID: 84857479028     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-12-5     Document Type: Article

References (43)

1. Soft tissue sarcoma. Epidemiology and prognosis in 508 patients. Gustafson P, Acta Orthop Scand Suppl 1994 259 1 31 8042499 (Pubitemid 24227011)
2. Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Engellau J, Anderson H, Rydholm A, Bauer HC, Hall KS, Gustafson P, Akerman M, Meis-Kindblom J, Alvegard TA, Nilbert M, Cancer 2004 100 2233 2239 10.1002/cncr.20254 15139069 (Pubitemid 38580345)
3. Surgical margin and its influence on survival in soft tissue sarcoma. Dickinson IC, Whitwell DJ, Battistuta D, Thompson B, Strobel N, Duggal A, Steadman P, ANZ J Surg 2006 76 104 109 10.1111/j.1445-2197.2006.03615.x 16626341 (Pubitemid 43363007)
4. The outcomes and prognostic factors of patients with soft-tissue sarcoma. Kiatisevi P, Asavamongkolkul A, Phimolsarnti R, Waikakul S, Benjarassamerote S, J Med Assoc Thai 2006 89 334 342 16696417
5. Histopathologic type: an independent prognostic factor in primary soft tissue sarcoma of the extremity? Koea JB, Leung D, Lewis JJ, Brennan MF, Ann Surg Oncol 2003 10 432 440 10.1245/ASO.2003.05.014 12734093 (Pubitemid 40486942)
6. Retroperitoneal soft tissue sarcoma. Mendenhall WM, Zlotecki RA, Hochwald SN, Hemming AW, Grobmyer SR, Cance WG, Cancer 2005 104 669 675 10.1002/cncr.21264 16003776 (Pubitemid 41113665)
7. Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the Intergroup Rhabdomyosarcoma Study I. Raney RB Jr, Crist WM, Maurer HM, Foulkes MA, Cancer 1983 52 44 50 6850544 (Pubitemid 13057606)
8. High grade soft tissue sarcoma of the flexor fossae. Size rather than compartmental status determine prognosis. Yang RS, Lane JM, Eilber FR, Dorey FJ, al Shaikh R, Schumacher LY, Rosen G, Forscher CA, Eckardt JJ, Cancer 1995 76 1398 1405 10.1002/1097-0142(19951015)76:8<1398::AID-CNCR2820760815>3.0. CO;2-B 8620414
9. Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Int J Radiat Oncol Biol Phys 2003 57 739 747 10.1016/S0360-3016(03)00714-4 14529779 (Pubitemid 37194300)
10. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Wakabayashi O, Yamazaki K, Oizumi S, Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H, Nishimura M, Cancer Sci 2003 94 1003 1009 10.1111/j.1349-7006. 2003.tb01392.x 14611679 (Pubitemid 37521216)
11. Prognostic impact of lymphocytes in soft tissue sarcomas. Sorbye SW, Kilvaer T, Valkov A, Donnem T, Smeland E, Al Shibli K, Bremnes RM, Busund LT, PLoS One 2011 6 14611 10.1371/journal.pone.0014611 21298041
12. Paradoxical roles of the immune system during cancer development. de Visser KE, Eichten A, Coussens LM, Nat Rev Cancer 2006 6 24 37 10.1038/nrc1782 16397525 (Pubitemid 43053650)
13. The role of tumor stroma in the interaction between tumor and immune system. Blankenstein T, Curr Opin Immunol 2005 17 180 186 10.1016/j.coi.2005.01. 008 15766679 (Pubitemid 40343106)
14. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Mukai S, Kjaergaard J, Shu S, Plautz GE, Cancer Res 1999 59 5245 5249 10537304 (Pubitemid 29503989)
15. Immune escape as a fundamental trait of cancer: focus on IDO. Prendergast GC, Oncogene 2008 27 3889 3900 10.1038/onc.2008.35 18317452 (Pubitemid 351913639)
16. Tumor escape from immune surveillance. Costello RT, Gastaut JA, Olive D, Arch Immunol Ther Exp (Warsz) 1999 47 83 88
17. CD4+ CD25high regulatory T cells reduce T cell transendothelial migration in cancer patients. Enarsson K, Lundin BS, Johnsson E, Brezicka T, Quiding-Jarbrink M, Eur J Immunol 2007 37 282 291 10.1002/eji.200636183 17163448 (Pubitemid 46128808)
18. Biological prognostic factors in adult soft tissue sarcomas. Ottaiano A, De Chiara A, Fazioli F, Talamanca AA, Mori S, Botti G, Milano A, Apice G, Anticancer Res 2005 25 4519 4526 16334136 (Pubitemid 41729506)
19. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA, J Clin Oncol 2002 20 2417 2428 10.1200/JCO.2002.08.159 12011119 (Pubitemid 34525727)
20. Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Donnem T, Al Saad S, Al Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT, Bremnes RM, Clin Cancer Res 2007 13 6649 6657 10.1158/1078-0432.CCR-07-0414 18006765 (Pubitemid 350206800)
21. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Nocito A, Kononen J, Kallioniemi OP, Sauter G, Int J Cancer 2001 94 1 5 10.1002/ijc.1385 11668471 (Pubitemid 32801745)
22. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Al Shibli KI, Donnem T, Al Saad S, Persson M, Bremnes RM, Busund LT, Clin Cancer Res 2008 14 5220 5227 10.1158/1078-0432.CCR- 08-0133 18698040
23. Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Karja V, Aaltomaa S, Lipponen P, Isotalo T, Talja M, Mokka R, Anticancer Res 2005 25 4435 4438 16334122 (Pubitemid 41729492)
24. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH, PLoS One 2009 4 6412 10.1371/journal.pone.0006412 19641607
25. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis. Pelletier MP, Edwardes MD, Michel RP, Halwani F, Morin JE, Can J Surg 2001 44 180 188 11407827 (Pubitemid 32538769)
26. Cancer immunoediting: from immunosurveillance to tumor escape. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD, Nat Immunol 2002 3 991 998 10.1038/ni1102-991 12407406 (Pubitemid 35363648)
27. The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-small Cell Lung Cancer. Bremnes RM, Al Shibli K, Donnem T, Sirera R, Al Saad S, Andersen S, Stenvold H, Camps C, Busund LT, J Thorac Oncol 2011 6 824 833 10.1097/JTO.0b013e3182037b76 21173711
28. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. de Visser KE, Korets LV, Coussens LM, Cancer Cell 2005 7 411 423 10.1016/j.ccr.2005.04.014 15894262 (Pubitemid 40719125)
29. Vaccines against human carcinomas: strategies to improve antitumor immune responses. Palena C, Schlom J, J Biomed Biotechnol 2010 2010 380697 20300434
30. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Gooden M, Lampen M, Jordanova ES, Leffers N, Trimbos JB, van der Burg SH, Nijman H, van Hall T, Proc Natl Acad Sci USA 2011 108 26 10656 10661 10.1073/pnas.1100354108 21670276
31. A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Eerola AK, Soini Y, Paakko P, Clin Cancer Res 2000 6 1875 1881 10815910 (Pubitemid 30305084)
32. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Science 2006 313 1960 1964 10.1126/science.1129139 17008531 (Pubitemid 44498003)
33. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB, Clin Cancer Res 2004 10 4450 4456 10.1158/1078-0432.CCR-0732-3 15240536 (Pubitemid 38878888)
34. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H, Cancer Res 1998 58 3491 3494 9721846 (Pubitemid 28376536)
35. Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S, Katoh H, J Surg Oncol 2003 84 224 228 10.1002/jso.10321 14756433 (Pubitemid 37484787)
36. Effector memory T cells, early metastasis, and survival in colorectal cancer. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. N Engl J Med 2005 353 2654 2666 10.1056/NEJMoa051424 16371631 (Pubitemid 41817714)
37. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Schumacher K, Haensch W, Roefzaad C, Schlag PM, Cancer Res 2001 61 3932 3936 11358808 (Pubitemid 32720953)
38. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, et al. Proc Natl Acad Sci USA 2007 104 3967 3972 10.1073/pnas.0611618104 17360461 (Pubitemid 47181562)
39. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Staibano S, Mascolo M, Tranfa F, Salvatore G, Mignogna C, Bufo P, Nugnes L, Bonavolonta G, De Rosa G, Int J Immunopathol Pharmacol 2006 19 171 179 16569355
40. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Wahlin BE, Sander B, Christensson B, Kimby E, Clin Cancer Res 2007 13 388 397 10.1158/1078-0432.CCR- 06-1734 17255259 (Pubitemid 46225341)
41. Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein. Sun J, Zhao L, Teng L, Lin F, Zhang H, Li Z, Gao Q, PLoS One 2011 6 16642 10.1371/journal.pone.0016642 21311755
42. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW, Cancer Immunol Immunother 2009 58 3 449 459 10.1007/s00262-008-0583-5 18791714
43. CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection. Hong C, Lee H, Oh M, Kang CY, Hong S, Park SH, J Immunol 2006 177 6747 6757 17082588 (Pubitemid 44715039)